Literature DB >> 11793379

Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice.

Masaki Kawamura1, Taichi Naito, Masamichi Ueno, Takami Akagi, Katsuya Hiraishi, Izumi Takai, Masahiko Makino, Takeshi Serizawa, Kazuhisa Sugimura, Mitsuru Akashi, Masanori Baba.   

Abstract

Concanavalin A-immobilized polystyrene nanospheres (Con A-NS) were developed for the HIV-1 vaccine capable of preventing sexual transmission. Con A-NS could capture efficiently HIV-1 irrespective of their cell tropism (R5 or X4). Furthermore, Con A-NS captured equally infectious and heat-inactivated HIV-1. Inactivated HIV-1-capturing Con A-NS (HIV-NS) were intravaginally administered to mice. Heat-inactivated HIV-1 alone and Con A-NS alone were also administered as control immunogens. Vaginal fluids were collected during and after immunization and analyzed for their anti-HIV-1 antibody levels. Although the anti-HIV-1 IgG antibody was undetectable in any groups, increased anti-HIV-1 IgA antibody response was identified in the vaginal fluids of immunized mice with HIV-NS. The vaginal fluids obtained from the HIV-NS-administered mice showed neutralizing activity against the immunizing HIV-1 strain. A marked difference in vaginal distribution was observed between HIV-NS and other immunogens, and the toxicity of Con A was reduced by conjugation with nanospheres. Thus, HIV-NS may have great potential as a prophylactic HIV-1 vaccine and should be examined further for its efficacy in non-human primates. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11793379     DOI: 10.1002/jmv.2144

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

Review 1.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 2.  Vaginal delivery of vaccines.

Authors:  Hannah M VanBenschoten; Kim A Woodrow
Journal:  Adv Drug Deliv Rev       Date:  2021-09-01       Impact factor: 15.470

Review 3.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

4.  Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.

Authors:  Hiroshi Miyake; Yuji Iizawa; Masanori Baba
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

5.  Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.

Authors:  Xin Wang; Tomofumi Uto; Takami Akagi; Mitsuru Akashi; Masanori Baba
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.